Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?

Drug therapies for people with heart failure and preserved ejection fraction (HFpEF) are often limited to diuretics to improve symptoms as no therapies demonstrate a mortality benefit in this cohort. People with diabetes have a high risk of developing HFpEF and vice versa, suggesting shared pathophy...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, David M., Evans, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509021/
https://www.ncbi.nlm.nih.gov/pubmed/32852697
http://dx.doi.org/10.1007/s13300-020-00911-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509021/
https://www.ncbi.nlm.nih.gov/pubmed/32852697
http://dx.doi.org/10.1007/s13300-020-00911-0

Ejemplares similares